(Update: On November 4, 2021, the NIH provided a response to our comments on the license.) On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive… Continue Reading
On Monday March 23, 2020, Gilead Sciences’ remdesivir received orphan designation from the US Food and Drug Administration (FDA) for the treatment of COVID-19. Remdesivir has been reported to be one of the candidates to potentially treat COVID-19, which the… Continue Reading
On September 12, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Universities Allied for Essential Medicines (UAEM), Social Security Works (SSW), and Clare Love filed an appeal with the National Institutes of Health (NIH). The signatories appealed… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the National Institutes of Health (NIH) to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences. A copy of… Continue Reading
R 281104Z JUN 05 – June 28, 2005FM AMEMBASSY BRASILIATO SECSTATE WASHDC 1902SUBJECT: BRAZIL GIVES ABBOTT TEN DAYS BEFORE BREAKING PATENT 1. (U) SENSITIVE BUT UNCLASSIFIED 2. (U) Summary. On Friday June 24, the GoB announced a declaration of “public… Continue Reading
R 031944Z JUN 05 – June 3, 2005FROM: American Embassy BrasiliaTO: Secretary of State, Washington, D.C.SUBJECT: AMBASSADOR MEETS WITH U.S. PHARMACEUTICAL FIRMS THREATENED WITH LICENSING 1. (SBU) Summary. On May 24 and 25, U.S. pharmaceutical companies Gilead Sciences, Abbott Laboratories,… Continue Reading